01/14/2026
We were honored to have Dr. Steven Klein represent Caron Treatment Centers and our groundbreaking work on GLP-1 medications in addiction treatment at the Congressional Addiction, Treatment, and Recovery (ATR) Caucus in Washington, DC.
The ATR Caucus is a bipartisan group of Members of Congress dedicated to advancing solutions to our nation’s multifaceted addiction crisis. It is the first and longest-running Congressional Caucus to recognize addiction as a disease, and 2025 marks 21 years since its inception—bringing leaders together across party lines to fight stigma and save lives.
This year’s event featured Members of Congress, including Rep. Madeleine Dean of Pennsylvania and Paul Tonko of New York. Following the caucus, Dr. Klein spent the afternoon on Capitol Hill advocating for the responsible adoption of GLP-1 medications in addiction care and urging the FDA to support clearer, addiction-specific clinical outcomes in future studies.
We were also grateful to be joined by Nicholas Reville (CASPR.org) and Nick Horton (opendoorsri.org) for these important conversations.
At Caron, we are proud to be helping lead the future of addiction treatment—where science, compassion, and innovation come together to change and save lives.